Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

696.70 +1.71 (+0.25%)
Streaming Delayed Price Updated: 3:03 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
57 58 Next >
News headline image
Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ: WBA) from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2%... 
Via Benzinga
News headline image
Why Regeneron Stock Is Falling Today ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell after the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of... 
Via Benzinga
News headline image
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender ↗
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday. 
Via Investor's Business Daily
News headline image
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Where Regeneron Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗
 
Via Benzinga
News headline image
18 Analysts Have This to Say About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead ↗
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks. 
Via Talk Markets
News headline image
Biotech And Healthcare Stocks Lagging ↗
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade. 
Via The Motley Fool
News headline image
How to Retire Rich: Biotech Stocks Edition ↗
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
News headline image
Regeneron Pharmaceuticals Unusual Options Activity For June 05 ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71% ↗
 
Via Benzinga
News headline image
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
News headline image
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035 ↗
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and  
Via Benzinga
News headline image
2 Stocks to Buy No Matter What Happens in June and Beyond ↗
A lot could go wrong in the next few months, but investors should largely ignore all that noise. 
Via The Motley Fool
News headline image
3 Biotech Stocks to Sell in June Before They Crash and Burn ↗
Investors should get out of these biotech stocks to sell now that the Covid-19 pandemic is largely over. These's worse in store for them. 
Via InvestorPlace
News headline image
Wall Street Says These 2 Stocks May Double. Should You Buy Them? ↗
Both of these stocks have declined over the past year. 
Via The Motley Fool
News headline image
Regeneron Pharmaceuticals Unusual Options Activity For May 25 ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 5/19 Morning Trading
Via Investor Brand Network
News headline image
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
A Good Week For The Market But A Pause In The Biotech Rally ↗
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
News headline image
Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained ↗
 
Via Benzinga
News headline image
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.